Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.
Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M, Dudnik E, Studnicka M, Öhman R, Wurm R, Wannesson L, Peled N, Kian W, Bar J, Daher S, Addeo A, Rotem O, Pall G, Zer A, Saad A, Cufer T, Sorotsky HG, Hashemi SMS, Mohorcic K, Stoff R, Rovitsky Y, Keren-Rosenberg S, Winder T, Weinlinger C, Valipour A, Hochmair MJ. Illini O, et al. Among authors: kian w. Ther Adv Med Oncol. 2022 Jun 13;14:17588359221103206. doi: 10.1177/17588359221103206. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35720834 Free PMC article.
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.
Peled N, Kian W, Inbar E, Goldstein IM, Zemel M, Rotem O, Rozenblum AB, Nechushtan H, Dudnik E, Levin D, Zer A, Keren-Rosenberg S, Yust-Katz S, Fuchs V, Remilah AA, Shelef I, Roisman LC. Peled N, et al. Among authors: kian w. Neurooncol Adv. 2021 Dec 27;4(1):vdab188. doi: 10.1093/noajnl/vdab188. eCollection 2022 Jan-Dec. Neurooncol Adv. 2021. PMID: 35156036 Free PMC article.
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).
Raphael A, Onn A, Holtzman L, Dudnik J, Urban D, Kian W, Cohen AY, Moskovitz M, Zer A, Bar J, Rabinovich NM, Grynberg S, Oedegaard C, Agbarya A, Peled N, Shochat T, Dudnik E. Raphael A, et al. Among authors: kian w. Front Oncol. 2022 May 13;12:874712. doi: 10.3389/fonc.2022.874712. eCollection 2022. Front Oncol. 2022. PMID: 35646707 Free PMC article.
Liquid First Is "Solid" in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing.
Sehayek O, Kian W, Onn A, Stoff R, Sorotsky HG, Zemel M, Bar J, Dudnik Y, Nechushtan H, Rottenberg Y, Soussan-Gutman L, Dvir A, Roisman LC, Peled N. Sehayek O, et al. Among authors: kian w. Front Oncol. 2022 Jun 15;12:912801. doi: 10.3389/fonc.2022.912801. eCollection 2022. Front Oncol. 2022. PMID: 35785173 Free PMC article.
Lung cancer screening: a critical appraisal.
Kian W, Zemel M, Levitas D, Alguayn W, Remilah AA, Rahman NA, Peled N. Kian W, et al. Curr Opin Oncol. 2022 Jan 1;34(1):36-43. doi: 10.1097/CCO.0000000000000801. Curr Opin Oncol. 2022. PMID: 34652284 Review.
31 results